ICiCLe-ALL-14(InPOG-ALL-15-01)方案:印度新诊断儿童急性淋巴细胞白血病的前瞻性、风险分层、随机、多中心、开放标签、对照治疗试验
该方案针对印度新诊断儿童急性淋巴细胞白血病(ALL),基于细胞遗传学和微小残留病(MRD)水平进行风险分层,将患者分为四个风险组。2016年启动的多中心随机对照试验检验两项随机干预:缩短泼尼松诱导疗程(3周 vs 5周)对毒性的影响,以及用米托蒽醌替代多柔比星在延迟强化中的生存获益。主要结局包括无事件生存率、诱导期脓毒症发生率等。
要点
- 印度ICiCLe组2013年制定基于细胞遗传学和MRD的风险分层治疗方案,2016年启动ICiCLe-ALL-14随机试验。
- 四个风险组:标危(<10岁BCP-ALL、白细胞<50×10⁹/L、无高危特征)、中危、高危(含高危遗传学、中枢神经系统白血病、第8天泼尼松反应差、诱导末MRD≥0.01%)、T系ALL组。
- 两项随机:年轻非高危BCP-ALL中泼尼松诱导3周 vs 5周的毒性影响;延迟强化中用米托蒽醌替代多柔比星的生存获益。
核心结论
- ICiCLe-ALL-14是印度首个多中心儿童癌症随机临床试验,试验前阶段实现了风险分层诊断标准化并确立了协作实践、统一治疗、患者入组和数据采集的可行性。
- 试验前观察证实风险分层治疗可减少治疗相关死亡和费用,跨中心统一实践使患者能在本地获得治疗,可能减少经济负担和异地奔波。
研究设计与样本
- 前瞻性、风险分层、随机、多中心、开放标签、对照治疗试验,纳入1-18岁新诊断ALL患者。
- 根据起病特征、肿瘤遗传学和治疗反应将患者分为四个风险组:标危、中危、高危和T系ALL组。
- 所有患者接受四个强化治疗块(诱导、巩固、 interim维持、延迟强化)后接96周维持治疗,治疗强度按风险组调整。
- 临床数据管理基于网络远程数据采集系统。
- 试验注册:印度临床试验注册中心(CTRI)CTRI/2015/12/006434,注册日期2015年12月11日。
主要发现
- 标危组包括年龄<10岁、起病白细胞计数<50×10⁹/L且无高危特征的B细胞前体ALL(BCP-ALL)患者。
- 中危组包括无高危特征但年龄较大和/或起病白细胞计数高和/或有大包块病的BCP-ALL患者。
- 高危组包括具有任何高危特征的BCP-ALL患者,高危特征包括高危遗传学、中枢神经系统白血病、治疗第8天泼尼松反应差和诱导结束时高MRD(≥0.01%)。
- T系ALL患者构成第四风险组。
- 第一项随机比较年轻非高危BCP-ALL中泼尼松诱导3周 vs 5周的毒性影响;第二项随机比较延迟强化中米托蒽醌替代多柔比星 vs 多柔比星的生存获益。
关键数值与推荐
- 标危:年龄<10岁、BCP-ALL、起病白细胞计数<50×10⁹/L、无高危特征。
- 高危特征包括高危遗传学、中枢神经系统白血病、治疗第8天泼尼松反应差、诱导结束时MRD≥0.01%。
- 主要结局指标包括无事件生存率(总体及按风险组)、诱导期脓毒症发生率(第一项随机)和第二项随机后的无事件生存率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the west, survival following treatment of childhood acute lymphoblastic leukaemia (ALL) approaches 90%. Outcomes in India do not exceed 70%. To address this disparity, the Indian Collaborative Childhood Leukaemia group (ICiCLe) developed in 2013 a contemporary treatment protocol for uniform risk-stratified management of first presentation ALL based on cytogenetics and minimal residual disease levels (MRD). A multicentre randomised clinical trial opened in 2016 (ICiCLe-ALL-14) and examines the benefit of randomised interventions to decrease toxicity and improve outcomes. METHODS: Patients 1-18 years with newly diagnosed ALL are categorised into four risk groups based on presentation features, tumour genetics and treatment response. Standard risk includes young (< 10 years) B cell precursor ALL (BCP-ALL) patients with low presentation leucocyte count (< 50 × 109/L) and no high-risk features. Intermediate risk includes BCP-ALL patients with no high-risk features but are older and have high presentation leucocyte counts and/or bulky disease. High risk includes BCP-ALL patients with any high-risk feature, including high-risk genetics, central nervous system leukaemia, poor prednisolone response at treatment day 8 and high MRD (≥ 0·01%) at the end of induction. Patients with T-lineage ALL constitute the fourth risk group. All patients receive four intensive treatment blocks (induction, consolidation, interim maintenance, delayed intensification) followed by 96 weeks of maintenance. Treatment intensity varies by risk group. Clinical data management is based on a web-based remote data capture system. The first randomisation examines the toxicity impact of a shorter induction schedule of prednisolone (3 vs 5 weeks) in young non-high-risk BCP-ALL. The second randomisation examines the survival benefit of substituting doxorubicin with mitoxantrone in delayed intensification for all patients. Primary outcome measures include event-free survival (overall, by risk groups), sepsis rates in induction (first randomisation) and event-free survival rates following second randomisation. DISCUSSION: ICiCLe-ALL-14 is the first multicentre randomised childhood cancer clinical trial in India. The pre-trial phase allowed standardisation of risk-stratification diagnostics and established the feasibility of collaborative practice, uniform treatment, patient enrolment and data capture. Pre-trial observations confirm the impact of risk-stratified therapy in reducing treatment-related deaths and costs. Uniform practice across centres allows patients to access care locally, potentially decreasing financial hardship and dislocation. TRIAL REGISTRATION: Clinical Trials Registry-India (CTRI) CTRI/2015/12/006434 . Registered on 11 December 2015.
引用
- Das N, Banavali S, Bakhshi S, et al. Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. Trials. 2022. PMID: 35101099. doi:10.1186/s13063-022-06033-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。